Literature DB >> 14720084

Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations.

Miriam Romero1, Mayte Pérez-Olmeda, Javier García-Samaniego, Vicente Soriano.   

Abstract

Hepatitis C virus (HCV) infection is a significant public health problem and one of the most important causes of chronic liver disease worldwide. Co-infection with HCV and HIV occurs frequently, mainly because both viruses share the same transmission routes. In recent years, the life expectancy of patients with HIV disease has been increased due to the introduction of highly active antiretroviral therapy (HAART). Furthermore, several studies have established that HIV infection is associated with a major progression of the HCV-related liver disease. Thus, end-stage liver disease has become a leading cause of morbidity and mortality in this population, emphasising the importance of treatment of chronic hepatitis C in HIV-infected persons. The biological and histological benefit of interferon-alpha (IFNalpha) therapy in patients co-infected with HCV/HIV is not significantly different from that noted in similar patients without HIV when the HIV infection is adequately controlled. However, patients with low CD4+ cell counts tend to respond poorly to anti-HCV therapy.Given the relatively low sustained virological response rate to IFN alone, the use of IFNalpha monotherapy has been largely abandoned in favour of combination therapy with ribavirin. In the last 2 years, IFN plus ribavirin combination therapy has been the standard care for the treatment of chronic hepatitis C. Although information on the safety and efficacy of this dual therapy in HCV/HIV co-infected patients is scarce, recent trials have reported that the combination of IFN plus ribavirin is well tolerated and feasible in patients co-infected with HCV/HIV. However, the rates of sustained virological response seem to be worse than those observed in patients without HIV infection. New IFN formulations (e.g. pegylated interferon) plus ribavirin appear to be way of the future for the treatment of chronic hepatitis C in patients both with and without HIV co-infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14720084     DOI: 10.2165/00002018-200427010-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  89 in total

1.  Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy.

Authors:  M Pérez-Olmeda; J García-Samaniego; V Soriano
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

Review 2.  Management of chronic hepatitis C in HIV-infected patients.

Authors:  V Soriano; R Rodríguez-Rosado; J García-Samaniego
Journal:  AIDS       Date:  1999-04-01       Impact factor: 4.177

Review 3.  Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000.

Authors:  Javier García-Samaniego; Vicente Soriano; José María Miró; Jorge Del Romero; Miguel Bruguera; Jesús Castilla; Juan Ignacio Esteban; Juan Gonźlez; Eduardo Lissen; Alberto Moreno; Santiago Moreno; Ricardo Moreno-Otero; Enrique Ortega; Carmen Quereda; Manuel Rodríguez; José María Sánchez-Tapias
Journal:  HIV Clin Trials       Date:  2002 Mar-Apr

4.  Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients.

Authors:  R P Woitas; J K Rockstroh; I Beier; G Jung; B Kochan; B Matz; H H Brackmann; T Sauerbruch; U Spengler
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

5.  Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.

Authors:  A Lafeuillade; G Hittinger; S Chadapaud
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

Review 6.  Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

Authors:  T N Kakuda
Journal:  Clin Ther       Date:  2000-06       Impact factor: 3.393

7.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

8.  Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine.

Authors:  K Shriner; M B Goetz
Journal:  Am J Med       Date:  1992-07       Impact factor: 4.965

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin.

Authors:  H Meisel; A Reip; B Faltus; M Lu; H Porst; M Wiese; M Roggendorf; D H Krüger
Journal:  Lancet       Date:  1995-05-13       Impact factor: 79.321

View more
  5 in total

1.  Generalised Dermatitis Induced by Pegylated Interferon-alpha-2b in a Patient Infected with Genotype-1 Hepatitis C Virus : Presentation of a Case.

Authors:  L Gallelli; M Ferraro; G F Mauro; G De Sarro
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection.

Authors:  Greg L Plosker; Gillian M Keating
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  HCV co-infection in HIV positive population in British Columbia, Canada.

Authors:  Jane A Buxton; Amanda Yu; Paul H Kim; John J Spinelli; Margot Kuo; Maria Alvarez; Mark Gilbert; Mel Krajden
Journal:  BMC Public Health       Date:  2010-04-29       Impact factor: 3.295

4.  Community-based survey of HCV and HIV coinfection in injection drug abusers in Sichuan Province of China.

Authors:  Yu-Hua Ruan; Kun-Xue Hong; Shi-Zhu Liu; Yi-Xin He; Feng Zhou; Guan-Ming Qin; Kang-Lin Chen; Hui Xing; Jian-Ping Chen; Yi-Ming Shao
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

5.  Management of chronic hepatitis C virus in patients with HIV.

Authors:  Stephanie A Santos; Nickolas Kontorinis; Douglas T Dieterich
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.